Clinical Pharmacokinetics

, Volume 53, Issue 5, pp 409–427

Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations

Authors

  • Clara T. M. M. de Kanter
    • Department of Pharmacy864 Radboud university medical center
    • Nijmegen Institute for Infection, Inflammation and Immunity (N4i)Radboud University Medical Center
  • Joost P. H. Drenth
    • Department of GastroenterologyRadboud University Medical Center
  • Joop E. Arends
    • Department of Internal Medicine and Infectious DiseasesUniversity Medical Center
  • Henk W. Reesink
    • Department of Gastroenterology and HepatologyAcademic Medical Center
  • Marc van der Valk
    • Division of infectious DiseasesAcademic Medical Center
  • Robert J. de Knegt
    • Department of Gastroenterology and HepatologyErasmus University Medical Center
    • Department of Pharmacy864 Radboud university medical center
    • Nijmegen Institute for Infection, Inflammation and Immunity (N4i)Radboud University Medical Center
Review Article

DOI: 10.1007/s40262-014-0142-5

Cite this article as:
de Kanter, C.T.M.M., Drenth, J.P.H., Arends, J.E. et al. Clin Pharmacokinet (2014) 53: 409. doi:10.1007/s40262-014-0142-5

Abstract

Chronic hepatitis C is a global health problem. To prevent or reduce complications, the hepatitis C virus (HCV) infection needs to be eradicated. There have been several developments in treating these patients since the discovery of the virus. As of 1 January 2014, the drugs that are approved for treatment of chronic HCV infection are peginterferon-α, ribavirin, boceprevir, telaprevir, simeprevir and sofosbuvir. In this review we provide an overview of the clinical pharmacokinetic characteristics of these agents by describing their absorption, distribution, metabolism and excretion. In the pharmacodynamic part we summarize what is known about the relationships between the pharmacokinetics of each drug and efficacy or toxicity. We briefly discuss the pharmacokinetics and pharmacodynamics of chronic hepatitis C treatment in special patient populations, such as patients with liver cirrhosis, renal insufficiency or HCV/HIV coinfection, and children. With this knowledge, physicians, pharmacists, nurse practitioners, etc. should be educated to safely and effectively treat HCV-infected patients.

Copyright information

© Springer International Publishing Switzerland 2014